22028770|t|APOE genotype-function relationship: evidence of -491 A/T promoter polymorphism modifying transcription control but not type 2 diabetes risk.
22028770|a|BACKGROUND: The apolipoprotein E gene (APOE) coding polymorphism modifies the risks of Alzheimer's disease, type 2 diabetes, and coronary heart disease. Aside from the coding variants, single nucleotide polymorphism (SNP) of the APOE promoter has also been shown to modify the risk of Alzheimer's disease. METHODOLOGY/PRINCIPAL FINDINGS: In this study we investigate the genotype-function relationship of APOE promoter polymorphism at molecular level and at physiological level: i.e., in transcription control of the gene and in the risk of type 2 diabetes. In molecular studies, the effect of the APOE -491A/T (rs449647) polymorphism on gene transcription was accessed by dual-luciferase reporter gene assays. The -491 A to T substitution decreased the activity (p<0.05) of the cloned APOE promoter (-1017 to +406). Using the -501 to -481 nucleotide sequence of the APOE promoter as a 'bait' to screen the human brain cDNA library by yeast one-hybrid system yielded ATF4, an endoplasmic reticulum stress response gene, as one of the interacting factors. Electrophoretic-mobility-shift assays (EMSA) and chromatin immuno-precipitation (ChIP) analyses further substantiated the physical interaction between ATF4 and the APOE promoter. Over-expression of ATF4 stimulated APOE expression whereas siRNA against ATF4 suppressed the expression of the gene. However, interaction between APOE promoter and ATF4 was not -491A/T-specific. At physiological level, the genotype-function relationship of APOE promoter polymorphism was studied in type 2 diabetes. In 630 cases and 595 controls, three APOE promoter SNPs -491A/T, -219G/T (rs405509), and +113G/C (rs440446) were genotyped and tested for association with type 2 diabetes in Hong Kong Chinese. No SNP or haplotype association with type 2 diabetes was detected. CONCLUSIONS/SIGNIFICANCE: At molecular level, polymorphism -491A/T and ATF4 elicit independent control of APOE gene expression. At physiological level, no genotype-risk association was detected between the studied APOE promoter SNPs and type 2 diabetes in Hong Kong Chinese.
22028770	49	57	-491 A/T	DNAMutation	tmVar:c|SUB|A|-491|T;HGVS:c.-491A>T;VariantGroup:1;CorrespondingGene:348;RS#:449647;CorrespondingSpecies:9606;CA#:14662613
22028770	120	135	type 2 diabetes	Disease	MESH:D003924
22028770	158	174	apolipoprotein E	Gene	348
22028770	229	248	Alzheimer's disease	Disease	MESH:D000544
22028770	250	265	type 2 diabetes	Disease	MESH:D003924
22028770	271	293	coronary heart disease	Disease	MESH:D003327
22028770	427	446	Alzheimer's disease	Disease	MESH:D000544
22028770	683	698	type 2 diabetes	Disease	MESH:D003924
22028770	745	752	-491A/T	DNAMutation	tmVar:c|SUB|A|-491|T;HGVS:c.-491A>T;VariantGroup:1;CorrespondingGene:348;RS#:449647;CorrespondingSpecies:9606;CA#:14662613
22028770	754	762	rs449647	SNP	tmVar:rs449647;VariantGroup:1;CorrespondingGene:348;RS#:449647;CorrespondingSpecies:9606
22028770	857	868	-491 A to T	DNAMutation	tmVar:c|Allele|A,T|-491;VariantGroup:1;CorrespondingGene:348;RS#:449647;CorrespondingSpecies:9606
22028770	1049	1054	human	Species	9606
22028770	1077	1082	yeast	Species	4932
22028770	1109	1113	ATF4	Gene	468
22028770	1348	1352	ATF4	Gene	468
22028770	1395	1399	ATF4	Gene	468
22028770	1449	1453	ATF4	Gene	468
22028770	1540	1544	ATF4	Gene	468
22028770	1553	1560	-491A/T	DNAMutation	tmVar:c|SUB|A|-491|T;HGVS:c.-491A>T;VariantGroup:1;CorrespondingGene:348;RS#:449647;CorrespondingSpecies:9606;CA#:14662613
22028770	1675	1690	type 2 diabetes	Disease	MESH:D003924
22028770	1748	1755	-491A/T	DNAMutation	tmVar:c|SUB|A|-491|T;HGVS:c.-491A>T;VariantGroup:1;CorrespondingGene:348;RS#:449647;CorrespondingSpecies:9606;CA#:14662613
22028770	1757	1764	-219G/T	DNAMutation	tmVar:c|SUB|G|-219|T;HGVS:c.-219G>T;VariantGroup:2;CorrespondingGene:348;RS#:405509;CorrespondingSpecies:9606;CA#:14703614
22028770	1766	1774	rs405509	SNP	tmVar:rs405509;VariantGroup:2;CorrespondingGene:348;RS#:405509;CorrespondingSpecies:9606
22028770	1781	1788	+113G/C	DNAMutation	tmVar:c|SUB|G|+113|C;HGVS:c.+113G>C;VariantGroup:0;CorrespondingGene:348;RS#:440446;CorrespondingSpecies:9606;CA#:9505908
22028770	1790	1798	rs440446	SNP	tmVar:rs440446;VariantGroup:0;CorrespondingGene:348;RS#:440446;CorrespondingSpecies:9606
22028770	1847	1862	type 2 diabetes	Disease	MESH:D003924
22028770	1922	1937	type 2 diabetes	Disease	MESH:D003924
22028770	2011	2018	-491A/T	DNAMutation	tmVar:c|SUB|A|-491|T;HGVS:c.-491A>T;VariantGroup:1;CorrespondingGene:348;RS#:449647;CorrespondingSpecies:9606;CA#:14662613
22028770	2023	2027	ATF4	Gene	468
22028770	2189	2204	type 2 diabetes	Disease	MESH:D003924
22028770	Association	RS#:440446;HGVS:c.+113G>C;CorrespondingGene:348	MESH:D003924
22028770	Association	MESH:D003924	348
22028770	Association	RS#:405509;HGVS:c.-219G>T;CorrespondingGene:348	MESH:D003924
22028770	Positive_Correlation	MESH:D003924	RS#:440446;HGVS:c.+113G>C;CorrespondingGene:348
22028770	Positive_Correlation	MESH:D003924	RS#:405509;HGVS:c.-219G>T;CorrespondingGene:348
22028770	Association	MESH:D003327	348
22028770	Association	MESH:D000544	348
22028770	Association	MESH:D003924	RS#:440446;CorrespondingGene:348
22028770	Association	MESH:D003924	RS#:405509;CorrespondingGene:348
22028770	Association	MESH:D003924	348

